• Patient-Derived Gastric Cancer Assembloids

  2026-09-07

  Shapira-Netanelov and colleagues developed a patient-derived gastric cancer assembloid model that combines tumor organoids with matched stromal cell subpopulations from the same specimen. The study shows that stromal context alters gene expression and drug responsiveness, providing a more physiologically relevant framework for investigating tumor heterogeneity, resistance, and personalized treatment strategies.

• Pomalidomide (CC-4047) Research Guide

  2026-09-05

  Pomalidomide, also called CC-4047, is an immunomodulatory research compound used to study multiple myeloma, cytokine signaling, and erythroid progenitor cell differentiation. Product-dossier benchmarks include a 13 nM IC50 for LPS-induced TNF-alpha release and tumor-growth suppression in murine CNS lymphoma models.

• Primidone: A Causality Map for TRPM3 and RIPK1

  2026-09-04

  Primidone (Mysoline) is more than an established antiepileptic drug: it is a context-dependent probe of TRPM3 and RIPK1 biology. This evidence-weighted guide explains how to connect biochemical inhibition, cellular phenotypes, endocrine selectivity, and translational models without overstating causality.

• Angiotensin Peptides and SARS-CoV-2 Spike Binding

  2026-09-04

  Oliveira et al. show that naturally occurring angiotensin peptides can enhance SARS-CoV-2 spike binding to AXL, with shorter and N-terminally modified peptides producing the strongest effects. The work identifies a biochemical link between renin-angiotensin signaling and viral receptor interactions while remaining limited to antibody-based binding assays rather than infection or clinical outcomes.

• N3-kethoxal for NET DNA Structure Mapping

  2026-09-03

  N3-kethoxal offers a structure-sensitive way to investigate accessible guanines in extracellular-trap DNA. This article explains how its azide-enabled workflow can complement, but not replace, sequence-specific studies of NET–thrombin interactions and immunothrombosis.

• Amikacin (BAY416651) Resistance Research Workflows

  2026-09-03

  Amikacin (BAY416651) provides a practical phenotype-level readout for studies of multidrug-resistant Enterobacterales, while its relative resistance to many aminoglycoside-modifying enzymes supports cleaner mechanism comparisons. This guide connects broth microdilution, plasmid localization, conjugation, and strain typing into an integrated antibiotic resistance research workflow.

• Pam3CSK4: Designing Neuro-Immune Assays

  2026-09-02

  Pam3CSK4 provides a defined TLR1/2 agonist input for dissecting innate inflammatory signaling. This article develops an assay framework that pairs receptor-proximal immune measurements with the neuro-immune findings of a 2025 iScience study without conflating neural regulation with direct TLR activation.

• Vorinostat Workflows for Cancer Biology

  2026-09-02

  Build more informative Vorinostat experiments by separating growth arrest from true cell killing. This workflow combines dose-response design, orthogonal apoptosis measurements, and practical handling guidance for epigenetic modulation in oncology.

• Quizartinib (AC220) FLT3 Assay Workflow

  2026-09-01

  Build more informative FLT3 assays with Quizartinib (AC220), from rapid autophosphorylation readouts to AML viability and resistance models. This workflow also shows how FLT3-focused experiments can be extended—carefully and transparently—to blast-phase CML research.

• Entecavir Workflows for HBV Research

  2026-09-01

  Build reproducible HBV replication assays with Entecavir, from nanomolar dose–response testing to resistance-aware and translational study design. This guide combines practical handling, cccDNA-focused endpoints, and safety monitoring informed by a rare thrombocytopenia case.

• Dabigatran Workflows for Thrombin Inhibition Assays

  2026-08-31

  Dabigatran enables controlled inhibition of both free and fibrin-bound thrombin across thrombin-generation and clot-based assays. This workflow-focused guide explains concentration design, DAB-versus-DABG comparisons, assay selection, and practical troubleshooting for reproducible anticoagulation research.

• Nonselective β-Blockers and HCT Recovery

  2026-08-31

  The reference study shows that nonselective β-adrenergic receptor inhibition can delay hematopoietic regeneration after allogeneic hematopoietic cell transplantation, whereas β1-selective inhibition has a much smaller effect. By combining mouse transplantation experiments with human cohort analyses, the authors identify blocker selectivity, posttransplant chemotherapy, transplant type, and graft size as clinically relevant modifiers of engraftment.

• Omeprazole A2845: Practical Research Workflow

  2026-08-30

  Omeprazole (SKU A2845) provides a defined H+,K+-ATPase inhibitor for gastric acid secretion research and functional acid-formation assays. Its water and ethanol insolubility, DMSO solubility, storage requirements, and research-use-only status must be addressed before use in antiulcer activity studies or peptic ulcer disease models.

• Thioguanine: From Mechanism to Translation

  2026-08-29

  Thioguanine, also known as 6-thioguanine, is more than a legacy thiopurine immunosuppressant. This thought-leadership analysis connects HGPRT- and DNMT1-associated biology with cancer cell proliferation inhibition, inflammatory bowel disease treatment, and emerging EV71 virus inhibition, while defining practical validation steps for translational researchers.

• Ibotenic Acid: From Lesions to Circuit Logic

  2026-08-28

  Ibotenic acid is an NMDA receptor agonist that can reveal how local glutamatergic perturbation reshapes neural function. This guide connects its experimental use with a brain-to-spinal pain circuit study to improve model selection, controls, and interpretation.

7799 records 1/520 page Next 12345 下5页 Last page